AWHL · Aspira Women's Health Inc. · Insider Trading

48,708 shares vested on September 15, 2026. 24,354 shares vested on September 30, 2026. 24,355 shares will vest on October 15, 2026.

18,750 shares will vest on July 26, 2026. The remaining shares will vest in equal monthly installments over the next 9 months.

This form is being filed to correct the number of options awarded.

17,500 shares will vest on July 26, 2026. The remaining shares will vest in equal monthly installments over the next 9 months.

Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.

Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.

Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.

This report is being filed to correct the number and nature of shares held by Dr. Cohen on September 17, 2025, the number of shares held by Dr. Cohen's spouse on September 17, 2025 and the presentation of the warrants held on September 17, 2025.

This report is being filed to correct the number of shares indirectly held by Mr. Fraser on September 17, 2025 and the presentation of the warrants held on September 17, 2025.

Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.

The shares were acquired as payment to Dr. Cohen from another party in settlement of another property.

This report is being filed to correct the number and nature of shares held by Dr. Cohen on September 17, 2025, the number of shares held by Dr. Cohen's spouse on September 17, 2025 and the presentation of the warrants held on September 17, 2025.

25,000 shares will vest on September 2, 2026. The remaining shares will vest in equal monthly installments over the next 36 months.

Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock.

On August 22, 2024, the reporting person was granted 19,375 RSUs, 4,844 of which vested on June 4, 2025. The common stock into which such vested RSUs converted on June 4, 2025 is reported in Table I on this Form 4.

Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 23,750 RSUs, 5,937 of which vested on June 4, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024.

Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock.

On August 22, 2024, the reporting person was granted 33,750 RSUs, 8,437 of which vested on June 4, 2025. The common stock into which such vested RSUs converted on June 4, 2025 is reported in Table I on this Form 4.

Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 19,375 RSUs, 4,844 of which vested on June 4, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024.

Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock.

On August 22, 2024, the reporting person was granted 21,250 RSUs, 5,312 of which vested on June 4, 2025. The common stock into which such vested RSUs converted on June 4, 2025 is reported in Table I on this Form 4.

Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 33,750 RSUs, 8,437 of which vested on June 4, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024.

Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock

On March 11, 2025, the reporting person was granted 6,458 RSUs, 4,843 of which vested on June 4, 2025. The common stock into which such vested RSUs converted on June 4, 2025 is reported in Table I on this Form 4.

Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock

On August 22, 2024, the reporting person was granted 23,750 RSUs, 5,937 of which vested on June 4, 2025. The common stock into which such vested RSUs converted on June 4, 2025 is reported in Table I on this Form 4.

Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock.

On August 22, 2024, the reporting person was granted 20,625 RSUs, 5,156 of which vested on June 4, 2025. The common stock into which such vested RSUs converted on June 4, 2025 is reported in Table I on this Form 4.

Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On March 11, 2025, the reporting person was granted 6,458 RSUs, 4,843 of which vested on June 4, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 1, 2025.

Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 21,250 RSUs, 5,312 of which vested on June 4, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024.

Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 20,625 RSUs, 5,156 of which vested on June 4, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024.

The employee stock option will vest in forty-eight equal monthly amounts beginning January 30, 2025.

Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 20,625 RSUs, 5,156 of which vested on March 31, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024.

Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock.

On August 22, 2024, the reporting person was granted 33,750 RSUs, 8,438 of which vested on March 31, 2025. The common stock into which such vested RSUs converted on March 31, 2025 is reported in Table I on this Form 4.

Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock.

On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on March 31, 2025. The common stock into which such vested RSUs converted on March 31, 2025 is reported in Table I on this Form 4.

Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock

On March 11, 2025, the reporting person was granted 6,458 RSUs, 1,615 of which vested on March 31, 2025. The common stock into which such vested RSUs converted on March 31, 2025 is reported in Table I on this Form 4.

Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 33,750 RSUs, 8,438 of which vested on March 31, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024.

Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock.

On August 22, 2024, the reporting person was granted 21,250 RSUs, 5,313 of which vested on March 31, 2025. The common stock into which such vested RSUs converted on March 31, 2025 is reported in Table I on this Form 4.

Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On March 11, 2025, the reporting person was granted 6,458 RSUs, 1,615 of which vested on March 31, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on April 1, 2025.

Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 19,375 RSUs, 4,843 of which vested on March 31, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024.

Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock.

On August 22, 2024, the reporting person was granted 19,375 RSUs, 4,843 of which vested on March 31, 2025. The common stock into which such vested RSUs converted on March 31, 2025 is reported in Table I on this Form 4.

Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 21,250 RSUs, 5,313 of which vested on March 31, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024.

Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock

On August 22, 2024, the reporting person was granted 23,750 RSUs, 5,938 of which vested on March 31, 2025. The common stock into which such vested RSUs converted on March 31, 2025 is reported in Table I on this Form 4.

Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock.

On August 22, 2024, the reporting person was granted 20,625 RSUs, 5,156 of which vested on March 31, 2025. The common stock into which such vested RSUs converted on March 31, 2025 is reported in Table I on this Form 4.

Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 23,750 RSUs, 5,938 of which vested on March 31, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024.

Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On August 22, 2024, the reporting person was granted 20,000 RSUs, 5,000 of which vested on March 31, 2025. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on August 26, 2024.

Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock

1,615 RSUs will vest on March 31, 2025 and 4,843 RSUs will vest on date of the annual shareholders' meeting, subject to the Reporting Person's continued service to Aspira Women's Health Inc. through the applicable vesting dates.

On March 6, 2025, the Issuer issued to the Living Trust in a private transaction a Senior Secured Convertible Note due 2030 in the principal amount of $200,000 (the "Convertible Note"). Each $0.25 principal amount of the Convertible Note is convertible by its holder at any time prior to maturity into one "Phase 1 Unit," consisting of (i) one share of Common Stock and (ii) a warrant to purchase, on the terms set forth therein, 2.25 shares of Common Stock.

Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.